26289-09-8

Basic information

• Product Name: glycerophosphoserine
• Synonyms: glycerophosphoserine;glycerol 1-phosphoserine
• CAS NO: 26289-09-8
• Molecular Formula: C6H14NO8P
• Molecular Weight: 259.151021
• Mol File: 26289-09-8.mol

Chemical Properties

• Boiling Point: 572.7°C at 760 mmHg
• Flash Point: 300.1°C
• Appearance: /
• Density: 1.66g/cm³
• Vapor Pressure: 1.69E-15mmHg at 25°C
• Refractive Index: 1.551
• CAS DataBase Reference: glycerophosphoserine(CAS DataBase Reference)
• NIST Chemistry Reference: glycerophosphoserine(26289-09-8)
• EPA Substance Registry System: glycerophosphoserine(26289-09-8)

Safety Data

• Hazardous Substances Data: 26289-09-8(Hazardous Substances Data)

Usage

Uses

Used in Antioxidant Applications:
Glycerophosphoserine is used as an antioxidant in bamboo leaves, contributing to the plant's defense mechanisms against oxidative stress and promoting overall health and longevity.
Used in Hepatocellular Carcinoma Detection:
In the medical field, glycerophosphoserine serves as a useful tool for screening and identifying hepatitis B-related hepatocellular carcinoma. Its presence in the body can indicate the presence of this specific type of liver cancer, aiding in early diagnosis and treatment.
Used in Pharmaceutical Industry:
Glycerophosphoserine is used as a key compound in the development of new drugs and therapies, particularly in the treatment of various diseases and conditions. Its unique structure and properties make it a valuable asset in the design and synthesis of novel pharmaceutical agents.

InChI:InChI=1/C6H14NO8P/c7-5(6(10)11)3-15-16(12,13)14-2-4(9)1-8/h4-5,8-9H,1-3,7H2,(H,10,11)(H,12,13)/t4?,5-/m0/s1

Relevant articles and documents

Monoclonal antibody recognizing phosphatidylinositol-3,4-diphosphate

A novel monoclonal antibody that specifically recognizes phosphatidylinositol-3,4-biphosphate (PI-3,4-P2) but does not cross-react with structurally similar phospholipid antigens is advantageous for PI-3,4-P2-specific immunoassay. The gene in the variable regions of the monoclonal antibody has been identified, which enables producing recombinant antibodies.

Monoclonal antibody recognizing phosphatidylinositol-3,4,5-triphosphate

A monoclonal antibody that specifically recognizes phosphatidylinositol-3,4,5-triphosphate (PIP3) but does not cross-react with structurally similar phospholipid antigens is advantageous for PIP3-specific immunoassay. The gene in the variable regions of the monoclonal antibody has been identified, which enables producing recombinant antibodies.

Combinations of tyrosine, methylating agents, phospholipids, fatty acids, and St. John's Wort for the treatment of mental disturbances

This invention provides therapeutic compositions for the treatment or prevention of mental disturbances such as depressive states and for regulating the level of certain neurotransmitters and thereby improving the function of the central nervous system and cognitive function in humans and other animals. The therapeutic compositions comprise any two or more of tyrosine, one or more methylating agents, one or more phospholipids, one or more fatty acids and St. John's Wort (Hypericum perforatum), whether naturally, synthetically, or semi-synthetically derived. The invention also provides a method of administering these compositions to humans or animals in need thereof.

Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors

Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, having reporters comprising gas-filled microbubbles stabilised by monolayers of film-forming surfactants, the reporter being coupled or linked to at least one vector.